CELANESE
222 West Las Colinas Boulevard
Suite 900N
Irving, TX 75039
E: healthcare@celanese.com
W: vitaldose.com

CUSTOMIZED SUPPORT FOR SUSTAINED RELEASE DRUG DELIVERY THERAPIES

Celanese works closely with you as a strategic partner to create innovative controlled-release dosage forms for biologics, small molecules, and RNA to meet the goals of patient-centric therapies, improved medicine and better healthcare economics.

From FEASIBILITY to DEVELOPMENT to COMMERCIALIZATION

Our scientists and engineers are there from concept to commercialization, providing development services, material supply aligned with GMP principles and regulatory support through the Celanese Development & Feasibility Lab. Our objective is to help our customers reduce R&D time and improve the likelihood of successful drug commercialization.

INTRODUCING THE VITALDOSE^® PLATFORM

Our VitalDose^® Ethylene-Vinyl Acetate (EVA) copolymer drug-delivery platform is an enabling technology for drug-eluting implants and inserts. The platform is flexible and customizable to address and  tailor the release rate of your drug.

• Compatible with biologics, RNA, and small molecules
• Provides reliable local or systemic drug administration
• High drug loading capacity (≤ 75%)
• Achieves drug release over >6 months
• Ease of formulation and configurable into a variety of geometries
• An established regulatory path with long clinical use history

VitalDose^® EVA has been approved for use in numerous pharmaceutical and medical device applications. We are actively supporting marketed products and development programs in:

• Ophthalmic inserts & intraocular implants
• Oncology
• Women’s health
• Central nervous system disorders
• Rare diseases
• Endocrinology

ABOUT CELANESE

Celanese Corporation is a global technology leader in the production of differentiated chemistry solutions and specialty materials used in most major industries and consumer applications. We partner with our customers to solve their most critical business needs and strive to make a positive impact on our communities and the world through our commitment to sustainability and The Celanese Foundation. Based in Dallas, Celanese employs approximately 13,300 employees worldwide and had 2022 net sales of $9.7 billion.

Celanese has supported the demanding requirements of the medical and pharmaceutical markets for over 40 years, expanding possibilities alongside our customers. We’re focused on developing new cutting-edge approaches to improve patient care. Our portfolio includes solutions and technologies across applications including drug delivery, medical devices, implantable devices, advanced surgical instruments and connected devices.